Title | Authors (identified) | Published In | Identifier(s) | Topic | Published Date | Match? |
---|
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected | [1]Javier Sastre, [2]Virginia de la Orden, [3]Antonio Martínez, [4]Inmaculada Bando, [5]Milagros Balbín, [6]Beatriz Bellosillo, [7]Sarai Palanca, [8]Maria Isabel Peligros Gomez, [9]Beatriz Mediero, [10]Patricia Llovet, ..., [15]Maria José Ortiz-Morales, [16]Antonieta Salud, [17]Guillermo Quintero, [18]Carlos Lopez, [19]Eduardo Díaz-Rubio, ... [Full author list] | Clinical Colorectal Cancer [missing] | DOI: 10.1016/J.CLCC.2020.02.014 [ORCID] PubMed: 32278676 [ORCID]
| colorectal cancer [missing]; metastatic colon cancer [missing] | 2020-03-06 | |
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study | [1]Ana Fernández, [2]Mercedes Salgado, [3]Adelaida García, [4]Elvira Buxò, [5]Ruth Vera, [6]Jorge Adeva, [7]Paula Jiménez-Fonseca, [8]Guillermo Quintero, [9]Cristina Llorca, [10]Mamen Cañabate, ... [Full author list] | BMC Cancer [missing] | DOI: 10.1186/S12885-018-5101-3 [ORCID] PubMed: 30497432 [ORCID]
| pancreatic cancer [missing] | 2018-11-29 | |
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). | [1]Julen Fernandez-Plana, [2]Carlos Pericay, [3]Guillermo Quintero, [4]Vicente Alonso, [5]Antonieta Salud, [6]Miguel Mendez, [7]Mercedes Salgado, [8]Eugeni Saigi, [9]Luis Cirera, [10]ACROSS Study Group [Full author list] | BMC Cancer [missing] | DOI: 10.1186/1471-2407-14-865 [ORCID] PubMed: 25417182 [ORCID]
| colorectal cancer [missing]; cetuximab [missing]; phase II clinical trial [missing]; metastatic colon cancer [missing] | 2014-11-22 | |
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study. | [1]Mercedes Salgado, [2]Margarita Reboredo, [3]Juan Carlos Mendez, [4]Guillermo Quintero, [5]María Luz Pellón, [6]Carlos Romero, [7]Mónica Jorge, [8]Ana Fernández Montes, [9]Manuel Valladares-Ayerbes, [10]Manuel Ramos, [11]Silvia Varela, [12]Miguel Ángel Alonso, [13]Grupo Gallego De Investigaciones Oncológicas [Full author list] | Anticancer Research [missing] | PubMed: 24023354 [ORCID]
| colorectal cancer [missing]; capecitabine [missing] | 2013-09-01 | |
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer | [1]Carlos Grande, [2]Guillermo Quintero, [3]Sonia Candamio, [4]Lorena París Bouzas, [5]María José Villanueva, [6]Begoña Campos, [7]Elena Gallardo, [8]Elena Alvarez, [9]Joaquín Casal, [10]José Ramón Mel, [11]Grupo Gallego de Investigaciones Oncológicas (GGIO) [Full author list] | Journal of Geriatric Oncology [missing] | DOI: 10.1016/J.JGO.2013.01.001 [ORCID] PubMed: 24071536 [ORCID]
| colorectal cancer [missing]; capecitabine [missing]; oxaliplatin [missing]; metastatic colon cancer [missing] | 2013-02-16 | |